We established a cytotoxic T lymphocyte (CTL) clone reactive to WT1126−134 peptide from an HLA-A*02:01+ patient with acute myeloid leukemia (AML) with a favorable clinical response in our Wilms' tumor protein 1 (WT1)-targeted DC vaccination trial (ClinicalTrials.gov NCT00834002) and with polyepitope WT1-specific CTL responses (12) (Figure 1A). This evidence concerns the gene WT1 and acute myeloid leukemia.